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AbstrACt
Introduction Management of newly diagnosed type 1 
diabetes (T1D) in children and adolescents is challenging 
for patients, families and healthcare professionals. The 
objective of this study is to determine whether continued 
intensive metabolic control using hybrid closed- loop (CL) 
insulin delivery following diagnosis of T1D can preserve C- 
peptide secretion, a marker of residual beta- cell function, 
compared with standard multiple daily injections (MDI) 
therapy.
Methods and analysis The study adopts an open- label, 
multicentre, randomised, parallel design, and aims to 
randomise 96 participants aged 10–16.9 years, recruited 
within 21 days of diagnosis with T1D. Following a 
baseline mixed meal tolerance test (MMTT), participants 
will be randomised to receive 24 months treatment with 
conventional MDI therapy or with CL insulin delivery. A 
further 24- month optional extension phase will be offered 
to all participants to continue with the allocated treatment. 
The primary outcome is the between group difference 
in area under the stimulated C- peptide curve (AUC) of 
the MMTT at 12 months post diagnosis. Analyses will be 
conducted on an intention- to- treat basis. Key secondary 
outcomes are between group differences in time spent 
in target glucose range (3.9–10 mmol/L), glycated 
haemoglobin (HbA1c) and time spent in hypoglycaemia 
(<3.9 mmol/L) at 12 months. Secondary efficacy outcomes 
include between group differences in stimulated C- peptide 
AUC at 24 months, time spent in target glucose range, 
glucose variability, hypoglycaemia and hyperglycaemia 
as recorded by periodically applied masked continuous 
glucose monitoring devices, total, basal and bolus insulin 
dose, and change in body weight. Cognitive, emotional 
and behavioural characteristics of participants and parents 
will be evaluated, and a cost–utility analysis performed to 
support adoption of CL as a standard treatment modality 
following diagnosis of T1D.
Ethics and dissemination Ethics approval has been 
obtained from Cambridge East Research Ethics Committee. 
The results will be disseminated by peer- reviewed 
publications and conference presentations.
trial registration number NCT02871089; Pre- results.
IntroduCtIon
Type 1 diabetes (T1D) is characterised by 
insulin deficiency due to immune- mediated 
pancreatic beta- cell destruction.1 Incidence 
of T1D is increasing, particularly among chil-
dren.2 Management of newly diagnosed T1D 
in children and adolescents is challenging 
for patients, families and healthcare profes-
sionals. Furthermore, glycaemic control 
commonly deteriorates in adolescence due 
strengths and limitations of this study
 ► The study adopts an open- label, multicentre, ran-
domised, parallel design.
 ► The study includes youth newly diagnosed with type 
1 diabetes.
 ► The study includes a 4- year follow- up period with 
equal numbers of study visits between both groups.
 ► The comparator group can use pump therapy and/
or flash or continuous glucose monitoring devices or 
closed- loop systems if clinically appropriate.
 ► The study includes psychosocial assessments and 
health economic analysis to support adoption of 
closed- loop systems in this population.
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to physiological and psychological challenges relating 
to puberty. Most adolescents are unable to meet Inter-
national Society for Paediatric and Adolescent Diabetes 
(ISPAD) target glycated haemoglobin (HbA1c) <7.0% 
(53 mmol/mol).3 Fear of hypoglycaemia is common 
and affects quality of life and psychological well- being of 
children and families, leading to suboptimal glycaemic 
control.4
At clinical diagnosis of diabetes, most people retain 
some pancreatic islet cells that continue to secrete endog-
enous insulin for several years as reflected by C- peptide 
levels. In the Diabetes Control and Complications Trial, 
assignment to intensive therapy reduced the risk of loss of 
stimulated C- peptide by 57% over the mean 6.5- year study 
duration, showing that metabolic control was associated 
with preservation of islet cell function.5 Those with C- pep-
tide levels ≥0.20 pmol/mL initially or sustained over a 
year had fewer microvascular complications and fewer 
severe hypoglycaemic events.6 A linear relationship has 
been shown between frequency of retinopathy progres-
sion and plasma C- peptide as low as 0.03 pmol/mL.7
Emergence of new technologies including continuous 
glucose monitoring,8 sensor- augmented pump therapy9 
and threshold pump suspend10 11 provides opportunities 
to improve outcomes. The most promising approach is 
a closed- loop (CL) system which combines real- time 
glucose monitoring with computer- based algorithm- 
directed insulin delivery to achieve glucose- responsive 
subcutaneous insulin delivery mimicking beta- cell func-
tion.12 The first commercially available CL system, the 
MiniMed 670G pump (Medtronic, Northridge, Cali-
fornia), was launched in the USA in 2017 and in Europe 
in 2018.
The CL approach has been evaluated in children and 
adolescents in controlled laboratory studies13–15 and 
home settings.16–20 The results demonstrate improved 
glucose control and reduced risk of hypoglycaemia 
events. Psychosocial assessments support acceptability 
among children/adolescents and carers.21
We hypothesise that the CL approach using the 
Cambridge CL algorithm can preserve residual beta- cell 
function. The present study will assess the impact of CL 
insulin delivery after diagnosis on C- peptide secretion. We 
will also assess feasibility and acceptance of this therapy 
to support adoption as a standard treatment modality 
following diagnosis of T1D.
MEthods And AnAlysIs
overview
The study adopts an open- label, multicentre, randomised, 
single- period, parallel design to assess the effect of CL insulin 
delivery using the Cambridge CL algorithm from onset of 
T1D in youth on residual beta- cell function compared with 
standard insulin therapy (figure 1). Participants will include 
youths aged 10–16.9 years diagnosed with T1D within the 
previous 21 days. The study aims to randomise 96 partici-
pants. Recruited participants will be randomly assigned to 
24 months of study intervention. There will be an optional 
extension phase of a further 24 months of study interven-
tion online supplementary appendix.
The University of Cambridge (UK) will be the coordi-
nating centre. Clinical sites include:
1. Addenbrooke’s Hospital, Cambridge.
2. Leeds Children’s Hospital, Leeds.
3. Alder Hey Children’s Hospital, Liverpool.
4. Nottingham Children’s Hospital, Nottingham.
5. Oxford Children's Hospital, Oxford.
6. Southampton Children’s Hospital, Southampton.
7. Royal Hospital for Sick Children, Edinburgh.
Participants may also be recruited from Patient Iden-
tification Centres associated with these sites. Qualita-
tive interviews will be carried out by the University of 
Edinburgh.
Inclusion criteria
 ► Diagnosis of T1D (WHO criteria) within previous 21 
days.
 ► At least 10 years old and not older than 16.9 years.
 ► Participant/carer willing to perform regular capillary 
blood glucose monitoring (at least four blood glucose 
measurements every day).
 ► Literate in English.
 ► Willing to wear study devices.
 ► Willing to follow study- specific instructions.
 ► Willing to upload pump and continuous glucose 
monitoring (CGM) data at regular intervals.
Exclusion criteria
 ► Physical/psychological disease likely to interfere with 
the normal conduct of the study and interpretation of 
the study results as judged by the investigator.
 ► Current treatment with drugs known to interfere with 
glucose metabolism.
 ► Known or suspected allergy to insulin.
 ► Regular use of acetaminophen.
 ► Lack of reliable telephone facility for contact.
 ► Pregnancy, planned pregnancy or breast feeding.
 ► Living alone.
 ► Severe visual or hearing impairment.
 ► Medically documented allergy towards the adhesive of 
plasters or unable to tolerate tape adhesive in the area 
of sensor placement.
 ► Serious skin diseases located at places of the body 
used for localisation of the glucose sensor.
 ► Illicit drugs abuse.
 ► Prescription drugs abuse.
 ► Alcohol abuse.
 ► Sickle cell disease, haemoglobinopathy, receiving 
red blood cell transfusion or erythropoietin within 3 
months prior to time of screening.
 ► Eating disorder including anorexia/bulimia.
 ► Milk protein allergy.
study schedule
The study will consist of up to 14 visits and one telephone/
email contact in each arm over the 24- month study period. 
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Figure 1 Study flow including extension phase. CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin; MDI, 
multiple daily injection; MMTT, mixed meal tolerance test
The 24- month extension phase includes three visits and 
six clinic/telephone/email contacts (tables 1 and 2).
Following diagnosis and screening, written informed 
consent or assent (for minors) will be obtained from 
all participants and guardians before any study- related 
activities.
run-in and prerandomisation training
Participants and their families will receive structured 
diabetes education and training as per usual clinical 
practice in accordance with ISPAD guidelines.22 All 
participants will be trained on the multiple daily injec-
tion (MDI) regimen (online supplementary appendix). 
Within 3 weeks of diagnosis, participants will have a base-
line mixed meal tolerance test (MMTT).
randomisation
Eligible subjects will be randomised after baseline MMTT 
using remote central randomisation software to the use of 
the Cambridge CL insulin delivery system or to standard 
therapy. Randomisation will be stratified by site and age. 
The randomisation ratio will be 1:1 within each stratum. 
The randomisation list created by the study statistician is 
encrypted.
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Table 1 Schedule of study visits and contacts when the participant is randomised to day- and- night closed- loop (intervention 
group)
Visit/ contact Description
Start relative to previous/next 
visit/activity Duration
Run in period Visit 1 Recruitment and screening visit: consent/assent; 
inclusion, exclusion; screening blood sample
Within 21 days of diagnosis 2 hours
Visit 2 Baseline visit: HbA1c, MMTT, masked CGM, 
questionnaires, computerised cognitive testing, 
bloods for immunological analyses
7–21 days after diagnosis 3–4 hours
Randomisation
  Insulin pump and 
CGM training
Visit 3 Insulin pump training, initiation study pump Within 1 week of Visit 2 3–4 hours
Visit 4 CGM training, initiation of CGM Within 0–7 days of Visit 3 (Visit 4 
may coincide with Visit 3; training 
visits can be repeated)
2 hours
  Closed- loop insulin 
delivery (24 months)
*Visit 5 Closed- loop initiation at clinic/home Within 6 weeks of diagnosis 3–4 hours
Contact Review use of study devices, study update 1 week after Visit 5 (±3 days) <0.5 hour
*Visit 6 HbA1c, data download, masked CGM After 3 months of diagnosis (±1 
week)
<1 hour
Visit 7 MMTT, HbA1c, bloods for immunological 
analyses, data download, masked CGM, sleep 
quality assessment
After 6 months of diagnosis (±2 
weeks)
3–4 hours
*Visit 8 HbA1c, data download, masked CGM After 9 months of diagnosis (±2 
weeks)
<1 hour
Visit 9 MMTT, HbA1c, bloods for immunological 
analyses, data download, masked CGM, 
questionnaires, computerised cognitive testing, 
interviews, sleep quality assessment
After 12 months of diagnosis (±2 
weeks)
3–4 hours
*Visit 10 HbA1c, data download, masked CGM After 15 months of diagnosis (±2 
weeks)
<1 hour
*Visit 11 HbA1c, data download, masked CGM After 18 months of diagnosis (±2 
weeks)
<1 hour
*Visit 12 HbA1c, data download, masked CGM After 21 months of diagnosis (±2 
weeks)
<1 hour
*Visit 13 Masked CGM, sleep quality assessment Between Visit 12 and Visit 14 (Visit 
13 may coincide with visit 14)
<0.5 hour
Visit 14 End of closed- loop treatment:
MMTT, HbA1c, data download, bloods for 
immunological analyses, questionnaires, 
computerised cognitive testing, focus groups
After 24 months of diagnosis (±2 
weeks)
4–5 hours
Optional extension 
phase (24 months)
Contact Review use of study devices, HbA1c, study 
update
3 months after Visit 14 (±2 weeks) <0.5 hour
Contact Review use of study devices, HbA1c, study 
update
6 months after Visit 14 (±2 weeks) <0.5 hour
Contact Review use of study devices, HbA1c, study 
update
9 months after Visit 14 (±2 weeks) <0.5 hour
Visit 15 Fasted C- peptide and glucose, HbA1c, masked 
CGM, questionnaires
After 36 months of diagnosis (±2 
weeks)
<1 hour
Contact Review use of study devices, HbA1c, study 
update
3 months after Visit 15 (±2 weeks) <0.5 hour
Contact Review use of study devices, HbA1c, study 
update
6 months after Visit 15 (±2 weeks) <0.5 hour
Contact Review use of study devices, HbA1c, study 
update
9 months after Visit 15 (±2 weeks) <0.5 hour
*Visit 16 Masked CGM 2 weeks before Visit 17 (±2 weeks) <0.5 hour
Visit 17 Fasted C- peptide and glucose, HbA1c, masked 
CGM review, questionnaires
After 48 months of diagnosis (±2 
weeks)
<1 hour
*Could be done at home.
CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin; MMTT, mixed meal tolerance test.
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Table 2 Schedule of study visits/phone contacts when the participant is randomised to standard therapy that is, multiply daily 
injections (control group)
Visit/ contact Description
Start relative to previous/next 
visit/activity Duration
Run in period Visit 1 Recruitment and screening visit: consent/assent; 
inclusion, exclusion; screening blood sample
Within 21 days of diagnosis 2 hours
Visit 2 Baseline visit: HbA1c, MMTT, masked CGM, 
questionnaires, computerised cognitive testing, 
bloods for immunological analyses
7–21 days after diagnosis 3–4 hours
Randomisation
  Additional Training Visit 3 Training on carbohydrate counting Within 1 week of Visit 2 2 hours
Visit 4 Training on insulin dose adjustment Within 0–7 days of Visit 3 (Visit 4 
may coincide with Visit 3;
Training visits can be repeated)
2 hours
  Multiple daily injection of 
insulin (24 months)
*Visit 5 MDI arm start visit Within 6 weeks of diagnosis <1 hour
Contact Study update 1 week after Visit 5 (±3 days) <0.5 hour
*Visit 6 HbA1c, masked CGM After 3 months of diagnosis (±1 
week)
<1 hour
Visit 7 MMTT, HbA1c, bloods for immunological 
analyses, masked CGM, sleep quality 
assessment
After 6 months of diagnosis (±2 
weeks)
3–4 hours
*Visit 8 HbA1c, masked CGM After 9 months of diagnosis (±2 
weeks)
<1 hour
Visit 9 MMTT, HbA1c, bloods for immunological 
analyses, masked CGM, questionnaires, 
computerised cognitive testing, sleep quality 
assessment
After 12 months of diagnosis (±2 
weeks)
3–4 hours
*Visit 10 HbA1c, masked CGM After 15 months of diagnosis (±2 
weeks)
<1 hour
*Visit 11 HbA1c, masked CGM After 18 months of diagnosis (±2 
weeks)
<1 hour
*Visit 12 HbA1c, masked CGM After 21 months of diagnosis (±2 
weeks)
<1 hour
*Visit 13 Masked CGM, sleep quality assessment Between Visit 12 and Visit 14, (may 
coincide with visit 14)
<1 hour
Visit 14 End of closed- loop treatment:
MMTT, HbA1c, bloods for immunological 
analyses, questionnaires, computerised cognitive 
testing, focus groups
After 24 months of diagnosis (±2 
weeks)
4–5 hours
  Optional extension phase 
(24 months)
Contact Study update, HbA1c 3 months after Visit 14 (±2 weeks) <0.5 hour
Contact Study update, HbA1c 6 months after Visit 14 (±2 weeks) <0.5 hour
Contact Study update, HbA1c 9 months after Visit 14 (±2 weeks) <0.5 hour
Visit 15 Fasted C- peptide and glucose, HbA1c, masked 
CGM, questionnaires
After 36 months of diagnosis (±2 
weeks)
<1 hour
Contact Study update, HbA1c 3 months after Visit 15 (±2 weeks) <0.5 hour
Contact Study update, HbA1c 6 months after Visit 15 (±2 weeks) <0.5 hour
Contact Study update, HbA1c 9 months after Visit 15 (±2 weeks). <0.5 hour
*Visit 16 Masked CGM 2 weeks before Visit 17 (±2 weeks) <0.5 hour
Visit 17 Fasted C- peptide and glucose, HbA1c, masked 
CGM review, questionnaires
After 48 months of diagnosis (±2 
weeks)
<1 hour
*Could be done at home.
CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin; MDI, multiple daily injection; MMTT, mixed meal tolerance test.
Postrandomisation training
 Closed-loop
Participants randomised to the CL arm will be trained on 
the use of the study insulin pump and CGM sensor prior 
to starting CL insulin delivery. Competency on the use of 
study devices will be assessed.
Participants will use either the FlorenceM CL system 
(online supplementary appendix) and/or the follow- up 
CamAPS FX CL platform (online supplementary 
appendix). Participants can transit from FlorenceM 
to CamAPS FX at any time during the study and some 
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participants will use CamAPS FX from randomisation. 
The control algorithm is identical in both CL systems.
 Standard therapy (control intervention)
Participants will receive additional training sessions to 
complement the core training and to match contact time 
with the CL group. Participants will apply standard insulin 
therapy during the study period. Participants will be 
allowed to switch to insulin pump therapy and use flash/
continuous glucose monitoring or approved CL systems if 
clinically indicated applying National Institute for Health 
and Care Excellence (NICE) criteria according to usual 
clinical practice.
Contacts during 24-month home study period
Participants will have identical planned contact visits 
during the two study arms. Participants/parents will be 
contacted by email/telephone within 1 week after initia-
tion of the respective study arm. Thereafter, participants 
will be followed up at 3- monthly intervals. These study 
visits can take place at the hospital clinic, home or other 
suitable location. The purpose of these visits is to record 
any adverse events, device deficiencies, changes in insulin 
doses, other medical conditions and/or medications. An 
HbA1c sample will be taken and data from study devices 
downloaded. At each follow- up visit, participants of both 
study arms will be fitted with a masked CGM sensor. The 
sensor will be worn at home for up to 14 days. If the 
sensor fails or sensor function is interrupted prematurely, 
another sensor may be applied.
Routine clinical care will be provided by the local paedi-
atric diabetes team as per usual care. Throughout the 
trial, subjects/parents and/or the clinical team are free 
to adjust insulin therapy as per usual clinical practice, but 
no active treatment optimisation will be undertaken by 
the study team.
Participant withdrawal criteria
The following prerandomisation withdrawal criteria will 
apply:
1. Participant/family member is unable to demonstrate 
safe application of MDI therapy during run- in period as 
judged by the investigator
The following prerandomisation and postrandomisa-
tion withdrawal criteria will apply:
2. Participant is unable to demonstrate safe use of MDI 
or study insulin pump and/or CGM during postran-
domisation training as judged by the investigator.
3. Participant fails to demonstrate compliance with MDI 
therapy or study insulin pump and/or CGM during 
postrandomisation training.
4. Participants may terminate participation in the study 
at any time without necessarily giving a reason and 
without any personal disadvantage.
5. Significant protocol violation or non- compliance.
6. Recurrent severe hypoglycaemia events not related to 
the use of the CL system.
7. Recurrent severe hyperglycaemia event/DKA unre-
lated to infusion site failure and related to the use of 
the CL system.
8. Decision by the investigator or Sponsor that termina-
tion is in the participants best medical interest.
9. Allergic reaction to insulin.
10. Allergic reaction to adhesive surface of infusion set 
or glucose sensor.
11. If patient cannot be contacted in 12 weeks they will 
be considered lost to follow- up.
Withdrawn participants due to reasons 5–11 will be 
invited to undergo MMTT and provide blood samples at 
the end of the planned study intervention.
study ProCEdurEs
Mixed meal tolerance test
MMTTs will be conducted at baseline, 6, 12 and 24 months 
post diagnosis. MMTT will commence following an over-
night fast provided the participant’s blood glucose level is 
between 4 and 11.1 mmol/L. Long- acting insulin or basal 
infusion rates will continue as normal. Participants will be 
given a liquid meal (Boost, Nestle, Switzerland) according 
to bodyweight. Venous blood samples for measurement 
of C- peptide and plasma glucose will be collected 10 min 
prior to the meal, and at 0, 15, 30, 60, 90 and 120 min.
blood samples
Blood sampling schedule is shown in online supple-
mentary appendix. HbA1c will be measured centrally 
(Swansea University, UK) using an International Feder-
ation of Clinical Chemistry and Laboratory Medicine 
aligned method. Total cholesterol, triglycerides, high- 
density and low- density lipoproteins(HDL and LDL) will 
be measured locally. Plasma samples for C- peptide and 
glucose will be processed locally and stored deep frozen 
(−20°C or below) until analysis at central laboratory 
(Swansea University, UK). Blood samples for analysis of 
immune markers from plasma and peripheral mononu-
clear cells will be analysed centrally (JDRF/Wellcome 
Trust Diabetes and Inflammation Laboratory, Oxford, 
UK).
Masked CGM
Masked CGM (FreeStyle Libre Pro sensor; Abbott 
Diabetes Care, Alameda, California, USA) will be inter-
mittently applied throughout the trial. During run- in, 
masked CGM will serve to gain knowledge of the partic-
ipant’s glucose control characteristics before beginning 
either intervention arm. Postrandomisation, masked 
CGM will be applied following each 3- monthly study visit 
for 24 months. During the extension phase masked CGM 
will be applied every 12 months.
Psychosocial assessments
 Questionnaires
Participants and guardians will be invited to complete 
a series of questionnaires regarding quality of life at 
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baseline, 6, 12, 24, 36 and 48 months (details in online 
supplementary appendix).
 Computerised cognitive testing
Participants will complete selected subtests from a 
computerised test battery, Cogstate23 at baseline, 12 and 
24 months (online supplementary appendix). Cogstate 
has demonstrated sensitivity to subtle changes in cogni-
tion and is designed to accommodate repeated assess-
ment of a single individual.
 Measures of sleep quality
Quality and duration of sleep will be assessed subjectively 
in participants (Pittsburgh Sleep Quality Index (PSQI) 
and sleep diary) and guardians (PSQI). Participants will 
wear an Actiwatch (Philips Respironics, Bend, Oregon, 
USA) to provide objective measures of sleep and wake-
fulness based on motor activity. These measures will be 
conducted at 6, 12 and 24 months.
 Interviews
An integrated qualitative substudy will explore parents’ 
and youth’s views about using CL systems; the impact of 
using CL systems on diabetes management practices and 
everyday family life; parents’ and youth’s information and 
support needs when using CL systems; and their views 
about how the technology could be improved for future 
users. In- depth interviews will be undertaken at 12 months 
with a subset of up to 20 youth and 20 parents in the CL 
arm. Purposive sampling will be used to ensure diversity 
in terms of youth’s age and gender, parents’ occupation/
education and family forms. Where possible, parents and 
youth from the same family will be interviewed. Partici-
pants will be interviewed separately unless a joint inter-
view is requested. Recruitment to the interview study will 
continue until data saturation is achieved.
health economics
Health economic analysis will be performed contrasting 
CL and MDI therapy using a health economic simulation 
model: the IQVIA Core Diabetes Model (CDM). The CDM 
is a validated non- product- specific policy analysis tool for 
cost- effectiveness analysis in T1D.24 Baseline character-
istics of the simulation cohort will come from the trial. 
Treatment effects, both on risk factors and specific quality 
of life, will be based on the trial findings at 12 months for 
both arms. The base- case analysis will be performed from 
the perspective of the UK National Health Service. For 
treatment costs, only the incremental costs between the 
two arms (CL vs MDI) will be considered.
PAtIEnt And PublIC InvolvEMEnt
The research question and study endpoints are based 
on feedback from participants of previous studies and 
in line with prioritisation by stakeholders. Study design 
and assessment of the burden of the intervention were 
reviewed by focus groups. Results will be disseminated to 
participants and general public through social media and 
will be made available on the sponsor's website.
stAtIstICAl AnAlysIs
All analyses will be conducted on an intention- to- treat 
basis. Data from all randomised participants with/
without protocol violation including dropouts and with-
drawals will be included in the analysis. The statistical 
analysis plan can be found in the online supplementary 
information.
 Primary outcome analysis
The primary analysis will evaluate between group differ-
ences in the mean stimulated C- peptide AUC at 12 
months post diagnosis. The values will be compared using 
a linear model adjusting for baseline log (C- peptide AUC 
+1), gender, presence/absence of DKA at diagnosis and 
age as fixed effects, and clinical site as a random effect. 
HbA1c levels, body mass index (BMI) z- score and race/
ethnicity may also be included in the model as fixed 
effects to assess for the presence of confounding. The 
mean- adjusted difference between treatment groups 
and the corresponding 95% CI from the linear model 
will be reported. If residual values from the regression 
model have a skewed distribution then an appropriate 
alternate transformation or a non- parametric analysis 
based on ranks will be performed. Primary analysis will 
be a single comparison and no attempt will be formally 
made to control the overall type I error rate. The primary 
outcome will be tested at α=0.04.
 Key secondary endpoints
The following outcomes will be compared between treat-
ment groups at 12 months post diagnosis:
 ► Percent time in the target range (3.9–10.0 mmol/L).
 ► HbA1c.
 ► Percent time below 3.9 mmol/L.
These three endpoints will be tested in a hierarchical 
fashion in the order listed above. If C- peptide AUC is 
significant at α=0.04, then they will be tested at α=0.05. 
Otherwise, they will be tested at α=0.01. Likewise, if all 
three key endpoints are significant at α=0.01, then this 
alpha is recycled to the primary outcome and C- Peptide 
AUC will be tested at α=0.05. This process controls for the 
family- wise error rate. A diagram displaying this process is 
shown in the online supplementary appendix.
 Secondary efficacy endpoints
The following outcomes will be compared between treat-
ment groups at 6, 12 and 24 months post diagnosis and at 
36 and 48 months for subjects enrolling in the extension 
phase of the study.
 ► Mean stimulated C- peptide AUC (24 months).
 ► Fasting C- peptide/fasting glucose (36 and 48 months).
 ► HbA1c outcomes:
 – HbA1c levels.
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 – Percentage of patients in each group with 
HbA1c<7.5% (58 mmol/mol).
 ► CGM outcomes*
 – Percentage of time with sensor glucose readings in 
target (3.9 to 10 mmol/L).
 – Mean, SD, and coefficient of variation of sensor 
glucose levels.
 – Percentage of time with sensor glucose above tar-
get (10.0 mmol/L).
 – Percentage of time with sensor glucose levels in sig-
nificant hyperglycaemia (>16.7 mmol/L).
 – Percentage of time spent below target glucose (3.9 
mmol/L).
 – Percentage of time with sensor glucose levels<3.5 
mmol/L,<3.0 mmol/L and <2.8 mmol/L.
 – AUC of sensor glucose below 3.9 mmol/L and 3.5 
mmol/L.
 ► Total, basal and bolus insulin dose (units/day/kg).
 ► Change in BMI SD score.
 ► Blood pressure.
 ► Lipid profile.
*Glycaemic metrics will be based on masked sensor 
glucose levels collected at 3- monthly intervals during 
the trial. A single percentage will be calculated for each 
subject at each visit by pooling all CGM readings corre-
sponding to the 14- day period.
For all secondary endpoints, the false discovery rate will 
be controlled using the adaptive Benjamini- Hochberg 
procedure.
safety analysis
The following events will be compared between treat-
ment groups:
 ► Number of subjects with severe hypoglycaemic events.
 ► Number of episodes of severe hypoglycaemic events 
per subject and incidence rate/100- person years
 ► Number of subjects with Diabetic Ketoacidosis (DKA) 
events.
 ► Number of episodes of DKA events per subject and 
incidence rate/100- person years.
 ► Number of any other adverse events reported per 
subject.
 ► Number of any other severe adverse events reported 
per subject.
Safety data will be tabulated for all subjects in the 
two intervention periods, including dropouts and with-
drawals, irrespective of whether sensor glucose data are 
available and irrespective of whether CL was operational. 
For the binary safety outcomes, a repeated measures 
logistic regression model will be used to compare treat-
ment arms. For the count outcomes and the incidence 
rates, a Poisson regression model will be used.
Psychosocial evaluation
 Questionnaires
For each questionnaire, mean±SD score for each dimen-
sion and total score will be tabulated by treatment group, 
in addition to the distribution of responses for each 
individual question for both participant and parent 
version. The between- group difference of each score will 
be assessed using a linear model, adjusting for age, gender, 
presence of DKA at diagnosis and corresponding score at 
baseline, and adjusting for clinical site as a random effect.
 Cognitive testing
Change in cognitive test performance from baseline to 
follow- up at 12 and 24 months will be assessed, as a func-
tion of group (intervention or control).
 Sleep quality
The PSQI and actigraph data will be used to calculate 
mean total sleep quality score, sleep duration (sum of 
all epochs scored as sleep during the time in bed) and 
variability across nights, time in bed, sleep disturbance 
(including wake after sleep onset and number of awaken-
ings), latency, efficiency, quality and daytime dysfunction. 
Sleep data will be averaged across nights in each partici-
pant for each study period.
 Qualitative interview
Interview data will be analysed thematically using the 
constant comparison method. NVivo V.9, a qualitative 
software package, will be used to facilitate data coding/
retrieval.
 Focus groups
Transcripts of focus group discussions will be thematically 
analysed using QSR NVivo qualitative analysis software.
Protocol adherence will be analysed by treatment 
group.
health economics
Long- term outcomes derived from the simulation will 
include total direct costs, life expectancy, quality- adjusted 
life expectancy and time to onset of complications. Incre-
mental costs versus incremental effectiveness (quality- 
adjusted life years) for CL versus MDI therapy will be 
compared.
subgroup analysis
A random centre by treatment interaction effect will be 
explored for the primary outcome. Interpretation of any 
subgroup analyses will depend on whether the overall 
analysis demonstrates a significant treatment group 
difference. In the absence of a significant treatment 
effect in the primary analysis, interpretation of the centre 
by treatment interaction will be considered exploratory.
Per-protocol analysis
Per- protocol analysis limited to participants in the CL 
group who used CL for ≥60% of the time and in the MDI 
group who do not start insulin pump therapy will be 
conducted to compare the primary outcome, HbA1c and 
time with sensor glucose levels in target range.
Interim analysis
No formal interim analyses are planned.
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Power calculation
Assuming a mean area under the meal- stimulated 
C- peptide curve of 0.37 pmol/mL for the control group 
based on the lower 90% confidence limit from previous 
data,25 a 50% increase in the intervention group gives 
0.37*1.50=0.555 pmol/mL. After a ln(x+1) transforma-
tion, the mean values in the control and treatment groups 
are 0.315 and 0.441, respectively, giving a treatment effect 
of 0.126. The treatment effect of 0.126 with an SD of 
0.18 requires 44 subjects per group at 90% power for a 
two- sided test at the 0.05 level. Allowing for 10% loss to 
follow- up means we would need a total of 96 randomised 
participants.
study MAnAGEMEnt
Composition of study management groups is shown in 
the online supplementary appendix.
data Monitoring and Ethics Committee
An independent Data Monitoring and Ethics Committee 
(DMEC) will be notified of all serious adverse events 
and any unanticipated adverse device events that occur 
during the study. The DMEC will review compiled adverse 
event data at periodic intervals and will report to the Trial 
Steering Committee any safety concerns and recommen-
dations for suspension or early termination of the trial.
study sponsor
The study sponsors are the Cambridge University 
Hospitals NHS Foundation Trust and the University of 
Cambridge.
trial steering Committee
The trial steering committee will meet biannually to 
provide overall supervision of the trial including progress 
of the trial, adherence to the protocol, patient safety and 
the consideration of new information of relevance to the 
research question.
trial Management Group
The trial management group (TMG) will meet weekly 
and will be responsible for day- to- day management of the 
trial.
data management and monitoring
The study coordinators will be responsible for maintaining 
quality assurance and quality control systems to ensure 
that the trial is conducted and data are generated, docu-
mented and reported in compliance with the protocol, 
good clinical practice and regulatory requirements.
Confidentiality of participant data shall be observed at 
all times. Personal details for each participant taking part 
with a link to a unique identification number will be held 
locally on a study screening log in the Trial Site File at 
each study site. These details will not be revealed at any 
other stage during the study, and all results will remain 
anonymous.
Electronic case report forms will be used for recording 
anonymised study data and will be completed in accor-
dance with Good Clinical Practice and ISO 15197: 2013 
guidelines.
Indemnity
Any liability arising from study design will be covered by 
the clinical trial insurance policy organised by the Univer-
sity of Cambridge. National Health Service indemnity 
cover will apply for any claims arising from management 
and conduct of research.
EthICs And dIssEMInAtIon
All participants will be provided with oral and written 
information about the trial and procedures involved in 
the study before obtaining written informed consent/
assent.
Standard operating procedures for monitoring and 
reporting of all adverse events and adverse device effects 
will be in place including serious adverse events, serious 
adverse device effects and specific adverse events such as 
severe hypoglycaemia and significant hyperglycaemia with 
ketosis. Any substantial amendments to the protocol and 
other documents shall be notified to and approved by the 
independent REC and the regulatory authorities, prior to 
implementation as per nationally agreed guidelines.
Screening and recruitment commenced in January 
2017, and the study is expected to be completed by 
October 2023. Study results will be disseminated by peer- 
reviewed publications and conference presentations.
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